238 related articles for article (PubMed ID: 21993610)
1. What is the role of aldosterone excess in resistant hypertension and how should it be investigated and treated?
Sica DA
Curr Cardiol Rep; 2011 Dec; 13(6):520-6. PubMed ID: 21993610
[TBL] [Abstract][Full Text] [Related]
2. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
[TBL] [Abstract][Full Text] [Related]
3. Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure.
Sica DA
Methodist Debakey Cardiovasc J; 2015; 11(4):235-9. PubMed ID: 27057293
[TBL] [Abstract][Full Text] [Related]
4. The risks and benefits of therapy with aldosterone receptor antagonist therapy.
Sica DA
Curr Drug Saf; 2007 Jan; 2(1):71-7. PubMed ID: 18690952
[TBL] [Abstract][Full Text] [Related]
5. The risks and benefits of aldosterone antagonists.
Sica DA
Curr Heart Fail Rep; 2005 Aug; 2(2):65-71. PubMed ID: 16036053
[TBL] [Abstract][Full Text] [Related]
6. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
Lainscak M; Pelliccia F; Rosano G; Vitale C; Schiariti M; Greco C; Speziale G; Gaudio C
Int J Cardiol; 2015 Dec; 200():25-9. PubMed ID: 26404748
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological treatment of aldosterone excess.
Deinum J; Riksen NP; Lenders JW
Pharmacol Ther; 2015 Oct; 154():120-33. PubMed ID: 26213109
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C
Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561
[TBL] [Abstract][Full Text] [Related]
9. Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism.
Matsuda Y; Kawate H; Matsuzaki C; Sakamoto R; Shibue K; Ohnaka K; Anzai K; Nomura M; Takayanagi R
Endocr J; 2016; 63(3):249-55. PubMed ID: 26727302
[TBL] [Abstract][Full Text] [Related]
10. The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial.
Walsh M; Manns B; Garg AX; Bueti J; Rabbat C; Smyth A; Tyrwhitt J; Bosch J; Gao P; Devereaux PJ; Wald R
Clin J Am Soc Nephrol; 2015 Sep; 10(9):1602-8. PubMed ID: 26138259
[TBL] [Abstract][Full Text] [Related]
11. Mineralocorticoid receptor antagonists and endothelial function.
Maron BA; Leopold JA
Curr Opin Investig Drugs; 2008 Sep; 9(9):963-9. PubMed ID: 18729003
[TBL] [Abstract][Full Text] [Related]
12. Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses.
Fernet M; Beckerman B; Abreu P; Lins K; Vincent J; Burgess E
Vasc Health Risk Manag; 2018; 14():233-246. PubMed ID: 30275698
[TBL] [Abstract][Full Text] [Related]
13. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Moore TD; Nawarskas JJ; Anderson JR
Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
[TBL] [Abstract][Full Text] [Related]
14. Aldosterone antagonism: an emerging strategy for effective blood pressure lowering.
Pratt-Ubunama MN; Nishizaka MK; Calhoun DA
Curr Hypertens Rep; 2005 Jun; 7(3):186-92. PubMed ID: 15913492
[TBL] [Abstract][Full Text] [Related]
15. The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist.
Davis KL; Nappi JM
Clin Ther; 2003 Nov; 25(11):2647-68. PubMed ID: 14693297
[TBL] [Abstract][Full Text] [Related]
16. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
Khosla N; Kalaitzidis R; Bakris GL
Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
[TBL] [Abstract][Full Text] [Related]
17. Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study.
Agarwal R; Rossignol P; Garza D; Mayo MR; Warren S; Arthur S; Romero A; White WB; Williams B
Am J Nephrol; 2018; 48(3):172-180. PubMed ID: 30176673
[TBL] [Abstract][Full Text] [Related]
18. ARAs to the RESCUE.
Kaplan NM
J Am Soc Hypertens; 2016 Mar; 10(3):187-8. PubMed ID: 27408946
[No Abstract] [Full Text] [Related]
19. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease.
Pisoni R; Acelajado MC; Cartmill FR; Dudenbostel T; Dell'Italia LJ; Cofield SS; Oparil S; Calhoun DA
J Hum Hypertens; 2012 Aug; 26(8):502-6. PubMed ID: 21677673
[TBL] [Abstract][Full Text] [Related]
20. Comparison of agents that affect aldosterone action.
Tamargo J; Solini A; Ruilope LM
Semin Nephrol; 2014 May; 34(3):285-306. PubMed ID: 25016400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
